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Abstract
Introduction. Each of the steps involved in invasion of tumors requires specific molecu-
lar program in which the modulation of adhesive and migratory properties of disseminat-
ing cells plays an essential role. The improvement in the knowledge of these mechanisms 
can lead to discovery of new target candidates in drug development. In this study we 
focused attention on the product of the human AHI-1 (Abelson helper integration site) 
gene Jouberin (Jbn).
Methods. In particular, we explore by in vitro invasion assay, AHI-1 knockdown and 
electron microscopy, if Jbn is involved in the signaling machinery that regulates tumor 
invasion. To this purpose tumor cells of different histological derivation (brain, breast, 
skin) were employed. 
Results. We found that Jbn expression correlates with the proliferation, invasive poten-
tial and invasion strategy of the tested tumor cells, and that its downregulation reduces 
their capability of migrating and invading the extracellular matrix. 
Conclusions. The results obtained in this study for the first time point to Jbn as a new 
candidate involved in the invasion process of tumor cells, and as potential molecular 
target in anticancer therapy.
INTRODUCTION
The migratory and invasive properties of cancer cells 
is one of the features that most contributes to the can-
cer progression. However, the molecular mechanisms 
of metastasis are poorly understood. Given its impor-
tance, it is of interest to better understand the molecu-
lar mechanisms that regulate this complex and dynamic 
process. 
Each of the steps involved in this process requires 
specific molecular program in which the modulation of 
the adhesive and migratory properties of the dissemi-
nating tumor cells plays an essential role. Adhesive and 
migratory processes involve adhesion receptor families, 
receptor tyrosine kinases (such as ERK, FAK and AKT), 
cytoskeleton proteins, adapter and signalling proteins 
that interplay in a complex scenario, not yet fully under-
stood [1]. The improvement in the knowledge of mech-
anisms behind cell migration/invasion can lead to dis-
covery of new target candidates in drug development. 
In this work, we focused attention on the product 
of the human AHI-1 (Abelson helper integration site) 
gene Jouberin (Jbn), also identified as “Abelson helper 
integration site 1 protein homolog”. The Ahi-1 locus 
was initially identified as a common helper provirus in-
tegration site in 16% of Abelson murine leukemia virus 
(A-MuLV)-induced pre-B lymphomas [2].
The Ahi-1/AHI-1 gene is highly conserved in mam-
mals and encodes a unique protein with one Src ho-
mology 3 (SH3) domain, multiple proline-rich motifs 
(PXXP) SH3-binding sites, and seven WD40-repeats, 
all known mediators of protein-protein interaction. 
PEST sequences and tyrosine kinase phosphorylation 
sites are also contained [3]. Both murine and human 
Ahi-1/AHI-1 genes encode at least three isoforms and 
thus this gene is also subject to alternative splicing in 
normal cells. Human AHI-1 isoform II, the shortest 
isoform, lacks the SH3 domain and isoform III, which 
is still shorter than isoform I, contains additional cod-
ing sequences in its C-terminus which are absent from 
both isoform I and II [4]. Interestingly, Jbn is the only 
protein thus far identified to contain both WD40 re-
peats and a SH3 domain. Moreover, the human AHI-1 
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protein contains a coiled-coil domain in its N-terminal 
region, also involved in protein-protein interactions [5], 
which is entirely absent in the mouse and rat Ahi-1 pro-
teins [3]. Thus AHI-1 has multiple features of a unique 
adaptor protein regulating specific signaling pathways 
[4]. Normally Ahi-1/AHI-1 transcript levels are down-
regulated during both early murine and human hemato-
poietic cell differentiation [6].
Mutations in human AHI-1 gene encoding Jbn have 
been associated with pathological conditions such as 
Joubert syndrome, an autosomal recessive brain disor-
der with cerebellar ataxia, oculomotor apraxia, hypoto-
nia, neonatal breathing abnormalities and psychomotor 
delay [7-9]. In individuals with point mutations in hu-
man AHI-1, particularly within the WD40-repeat and 
SH3 domains, an abnormal development and axonal 
decussation is found [9]. In mouse, when Ahi-1 pro-
tein interacts with Huntingtin-associated protein 1 it 
forms a stable complex that is critical for neonatal de-
velopment [10]. AHI-1 isoforms and its mutations also 
underlie other diseases, including Joubert syndrome-
associated nephronophthisis and autism, and metabolic 
syndromes, such as type 2 diabetes [9, 11-15].
Evidence for an oncogenic role of AHI-1 has been 
reported. Ahi-1/AHI-1 transcript levels are highly up-
deregulated in certain human leukemic cells, including 
leukemic stem cells from patients with chronic myeloid 
leukemia (CML) and leukemic Sezary cells in cutane-
ous T-cell lymphoma (CTCL) [6, 13]. Moreover, over-
expression of Ahi-1 alone in primitive hematopoietic 
cells confers a proliferative advantage in vitro and in-
duces a lethal leukemia in vivo [15].
Strikingly, Jbn is a positive modulator of the canonical 
Wnt pathway through facilitation of b-catenin nuclear 
translocation [16, 17], event associated with epithelial-
to-mesenchymal transition (EMT) process [18].
Thus, in this work, we explore if AHI-1 transcript Jbn 
is involved in the signaling machinery that regulates tu-
mor invasion. To this purpose tumor cells of different 
histological origin were employed. The results obtained 
in this study by in vitro invasion assay, AHI-1 knock-
down and electron microscopy for the first time point 
to Jbn as a new protein involved in the invasion process 
of tumor cells.
MATERIALS AND METHODS
Cell cultures
Established tumor cell lines from different histologi-
cal origin were used: human glioblastoma cells (brain/
right frontal parieto-occipital cortex: LN229 cells from 
ATCC), drug-resistant variant human melanoma cells 
(M14 ADR cells, selected from human cutaneous 
metastatic melanoma M14 cell line, in the laboratories 
of the Department of Technology and Health, Istituto 
Superiore di Sanità, Rome, Italy) and human breast 
adenocarcinoma cells (mammary gland/breast; derived 
from metastatic site: pleural effusion: MDA-MB-231 
and MCF-7 WT cells from ATCC).
LN229, MDA and MCF-7 cell lines were grown in 
DMEM (Euroclone, Pero, Italy) with high glucose; 
M14 ADR cell line was grown in RPMI 1640 (Euro-
clone). The media were supplemented with 1% non es-
sential amino acids, 1% L-glutamine, 100 IU/ml peni-
cillin, 100 IU/ml streptomycin, 10% fetal bovine serum 
(Euroclone) and 1% vitamins (HAM’S F-12 only) (Eu-
roclone). Cell lines were cultured at 37 °C in a 5% CO2 
humidified atmosphere in air. 
Growth curves
For growth curves, LN229, MDA and MCF-7 cells 
were detached and counted in a Neubauer camera at 
1:2 dilution with trypan blue dye exclusion. Viable cells 
were plated at a density of 2.5 x103 cells per well in 
24 well plates. Two wells for each cell line were seeded 
in each plate. After 24, 48, 72 and 96 h cells were de-
tached and counted in a Neubauer camera.
Invasion assays
To analyze invasive potential of tumor cell lines, the 
transwell chamber invasion assay was employed. Briefly, 
inserts (8.0 mm pore) (BD Biosciences, Erembodegem, 
Belgium) which stood in 6-well plates (Corning Inc., 
Corning, NY) were employed. Matrigel™ was diluted 
to 1 mg/ml in serum-free RPMI medium. 200 µl of 5 
mg/ml Matrigel™ were placed on the lower side of each 
insert. The insert and the plate were incubated over-
night at 4 °C. The following day, cells were harvested 
and suspended in RPMI. The inserts were washed with 
serum-free RPMI, then 1x106 cells were added to each 
insert and 3 ml of RPMI containing 10% FCS were 
added to the well underneath the insert. Cells were in-
cubated at 37 °C up to 24 hours. After this time, the 
inner side of the insert was wiped with a wet swab to 
remove the cells while the outer side of the insert was 
gently rinsed with PBS and stained with 0.25% crystal 
violet (Sigma) for 10 minutes, rinsed again and then 
allowed to dry. The inserts were then viewed under a 
CCD camera equipped Nikon (Tokyo, Japan). To cal-
culate the number of cells, membranes were analyzed 
by Image J program. The image processing techniques 
that were employed include thresholding and analysis 
of particles.
Scanning electron microscopy
For SEM analysis, the membranes containing cells 
were removed from the inserts. At the indicated times, 
membranes were fixed with 2% glutaraldehyde (Merck, 
Darmstadt, Germany) in 0.1 M cacodylate buffer (pH 
7.4) (Sigma-Aldrich Corporation, MO, USA) at room 
temperature for 30 minutes, post-fixed with 1% OsO4 
(Merck) in the same buffer, dehydrated through a grad-
ed ethanol series, critical point dried with CO2, and 
gold coated by sputtering. Samples were examined with 
a Cambridge Stereoscan 360 scanning electron micro-
scope (Cambridge Instruments Ltd, Cambridge, UK).
Knockdown of AHI-1 
For the inhibition of AHI-1 protein expression in 
M14 ADR, LN229, MDA and MCF-7 cell lines, RNA 
interference experiments were carried out according to 
the manufacturer’s protocol (Santa Cruz Biotechnol-
ogy, Inc. CA, USA). In particular, AHI1 siRNA (h) 
(sc-72465) and control siRNA-A (sc-37007) were em-
ployed.
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Western blotting
For the analysis of protein expression, western blot-
ting experiments were performed on cell lysates both in 
the absence and in the presence of migratory stimulus, 
performed as described in invasion assay, but in the ab-
sence of Matrigel™. After 24 h in transwell chambers, 
cells were harvested from the insert and subsequently 
washed twice in ice-cold Tris-buffered saline (TBS; 
20mM Tris-HCl, pH 7.6, 140 mM NaCl) and lysed at 
4 °C in 200 ml of lysis buffer (10 mM Tris-HCl, pH 7.6, 
50mM NaCl, 30 mM sodium pyrophosphate, 5 mM 
EDTA, 0.5% Nonidet P40, 1% Triton X-100, 50 mM 
NaF, 0.1 mM Na3VO4, 1 mM phenylmethylsulfonyl 
fluoride, and complete mini proteinase inhibitors). Cell 
lysates were obtained by centrifugation at 17000 g for 
30 minutes at 4 °C; protein concentration in the super-
natant was determined by DC Protein Assay (Bio-Rad 
Laboratories), and lysates were adjusted to equivalent 
concentrations with lysis buffer. Total cell lysate (10-40 
mg) was then separated on SDS-PAGE. Proteins were 
transferred to polyvinylidene difluoride membranes 
that were blocked for 1 hour at room temperature with 
5% BSA in TTBS. Incubations with primary antibodies 
(anti AHI-1; Santa Cruz Biotechnology) (anti p-AKT, 
p-ERK, p-FAK; Cell Signaling Technology, Danvers, 
MA, USA) and with horseradish peroxidase-conju-
gated secondary antibody were performed in blocking 
solution overnight at 4 °C and for 1 hour at room tem-
perature, respectively. Immunoreactive bands were vi-
sualized by the ECL kit (GE Healthcare Biosciences, 
Pittsburgh, PA, USA). For loading control, membranes 
were incubated with monoclonal anti-alpha-tubulin 
(Sigma Aldrich). The western blot densitometry values 
were normalized with those of the loading control.
Statistical analysis
Reported values are the means ± SD from three or six 
independent experiments. Statistical analyses were per-
formed using Wilconxon-Mann-Whitney test. P-values 
lower than 0.05 were considered significant.
RESULTS AND DISCUSSION
During invasion process tumor cells activate highly 
regulated intracellular network of pathways that are 
necessary for cell growth, replication, death, and sur-
vival. This complex intracellular signalling involves li-
gands, receptors, kinases, adapter molecules, transcrip-
tion factors, and other molecules, many with multiple 
roles and functions (Reviewed in [1, 19]) and other not 
yet known. Evidence for an oncogenic role of the prod-
uct of AHI-1 gene, the Jbn protein (AHI-1) has been 
reported. Overexpression of AHI-1 alone in primitive 
hematopoietic cells confers a proliferative advantage 
in vitro and induces a lethal leukemia in vivo [15]. Of 
interest, it has been recently demonstrated that AHI-1 
interact with ABL protein kinases in CML cells [20].
Thus, because of its putative oncogenic role [15] and 
link with ABL family of protein kinases [20], we was 
interested in investigating whether AHI-1 had a role 
in the invasive potential of tumor cells. Cell lines from 
human breast (MDA-MB-231, MCF-7 WT), brain 
(LN229) and skin (M14 ADR) cancers were used. The 
invasive potential (IP) of cancer cells was evaluated by 
using the “transwell chamber invasion assay”, since the 
invasive abilities of tumor cells in this assay are usually 
related to their in vivo invasion behavior [21, 22]. Tumor 
cell lines tested in this study featured different IP (Fig-
ure 1, panels A and B). The IP was positively related to 
cell growth rate (Supplementary data 1 available online). 
In particular, human breast cancer estrogen triple nega-
tive MDA-MB-231 cells showed the highest capacity 
of invading the MatrigelTM (i.e. they occupied 40% of 
the lower side-membrane area) especially when com-
pared with estrogen-receptor positive MCF-7 WT cells 
(7.5%). The LN229 cells derived from patient with right 
frontal parieto-occipital glioblastoma were more effi-
cient (26.7%) than the M14 ADR cells (22.6%), resis-
tant variants derived from human cutaneous metastatic 
melanoma M14 cell line [23]. 
The combination of 2D and 3D in vitro assays, bio-
chemical tests and ultrastructural investigations by 
scanning electron microscopy (SEM) proved to be par-
ticularly suitable for the investigation of tumour cell 
migration and invasion [24]. Thus, we performed SEM 
observations to analyse the behaviour of tested tumour 
cells on membranes employed in “transwell chamber in-
vasion assay” (Figures 2 and 3). The experiments were 
carried out either in the absence of MatrigelTM film 
(migration) (Figure 2), in order to analyse the behaviour 
of tumour cells without the stimulus of ECM proteins, 
or in the presence of a MatrigelTM film, gelled on the 
lower side of the porous membranes (invasion) (Figure 
3). 3D imaging offered by SEM [24] can provide evi-
dence of “individual” or “collective” behaviour adopted 
by tumour cells to migrate through membranes or to in-
vade Matrigel™. In the first one, cells detach from the 
cell population and pass through the pores separately. 
In the “collective behaviour” cells move on the upper 
side of the porous membrane in clusters closely linked 
each other. As showed in Figure 2A, MDA-MB-231 
cells with the highest IP adhered to the membrane as 
separated cells, except for dividing ones. They also pref-
erentially move through the membrane pores as single 
cells, thus adopting an “individual behaviour”. Accord-
ingly to quantitative data by transwell chamber inva-
sion assay, SEM observations revealed a high number 
of MDA-MB-231 cells that migrated to the lower side 
of the porous membranes (Figure 2B). Similarly, a high 
number of LN229 cells was seen on the lower side of the 
migration membrane (Figure 2D), but differently from 
MDA-MB-231 cells they tended to form little chains on 
the upper side (Figure 2C). On the contrary, M14 ADR 
cells (Figures 2E and 2F) and MCF-7 WT cells (Figures 
2G and 2H), that featured a low IP when compared to 
LN229 and MDA-MB-231 cells, appeared to be tightly 
clustered on the upper side of the porous membranes. 
Thus, they adopted a “collective behaviour”. Also in this 
case, SEM observations confirmed quantitative data, 
since very few M14 ADR and MCF-7 WT cells were 
observed on the lower side of the filters (Figures 2F and 
2H, respectively). 
SEM allowed us to look in the details of the ECM-
cell interaction during the invasion process. On the low-
er side of the porous membranes covered with gelled 
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MatrigelTM cell protrusions interacting with extracel-
lular matrix are showed (Figures 3B-H). Literature data 
report two types of behaviour adopted by cancer cells 
to invade the extracellular matrix, “mesenchymal” and 
“ameboid” type, depending on the presence or the ab-
sence of focused proteolysis, respectively [25]. An area 
of MatrigelTM degradation was seen around the inva-
dopode when SEM observations were performed on the 
lower side of MDA-MB-231 and LN229 cell samples 
(Figure 3B and D). The invadopode of M14 ADR cells 
(Figure 3F) was able to penetrate the extracellular ma-
trix, apparently without degrading it, suggesting that an 
“amoeboid behaviour” was adopted. The MCF-7 WT 
cells with the lowest IP scarcely invaded the extracel-
lular matrix on the lower side of porous membranes 
(Figure 3H). 
Subsequently, we evaluated the AHI-1 expression in 
MDA-MB-231, LN229, M14 ADR, and MCF-7 cells 
either in absence or in presence of the migratory stimu-
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Figure 1
Invasion potential and expression of Jouberin (Jbn) in tumor 
cells. (A) Images of tumor cells migrated on the lower side of 
porous membranes covered by MatrigelTM. (B) Invasion poten-
tial expressed as number of cells migrated on the lower side 
of porous membrane. Average + SD from six independent ex-
periments. (C) Western blot of tumor cells expressing Jbn in the 
absence or in the presence (asterisk) of migratory stimulus. (D) 
Densitometric analysis of Jbn expression reported in C. Aver-
age + SD from three independent experiments.
Figure 2
Scanning Electron Microscopy (SEM) observations of  tumor 
cell migration. (A, C, E, G) Upper side of porous membrane. (B, 
D, F, H) Lower side of porous membrane. (A, B) MDA-MB-231, (C, 
D) LN229, (E, F) M14 ADR (G, H) and MCF-7 WT cells. 3D imaging 
by SEM provided evidence of “individual” (A, B) or “collective” 
(E, G) behaviour adopted by tumour cells to migrate through 
membranes. Accordingly to quantitative data, SEM observa-
tions revealed a high number of MDA-MB-231 (B) and LN229 
(D) cells migrated to the lower side of the porous membranes. 
Conversely, few M14 ADR (F) and MCF-7 WT (H) cells were de-
tected.
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lus (chemotactic gradient). The results showed in Figure 
1, panels C and D, demonstrated that the expression 
of AHI-1 was positively related to the IP, as showed 
by the densitometric quantification in Western blotting 
(WB) experiments. Thus, MDA-MB-231 and LN229 
cells, which showed the highest IP in invasion assay, ex-
pressed Jbn levels higher than displayed by M14 ADR 
and MCF7 cells. Under migratory stimulus (Figure 1, 
panels C and D, samples with asterisk) an increase of 
O.D. was observed in MDA-MB-231 and LN229 cell 
samples, but it was not detectable in M14 and MCF-7 
cell ones. Thus, the highest espression of AHI-1 gene 
product in tumour cells featuring the most aggressive 
phenotype with highest IP and an invasive individual 
behaviour. 
In order to look insight the functional role of the AHI-
1 in the migration and invasion processes, RNA inter-
ference (siRNA) experiments were performed. MDA-
MB-231, LN229, M14 ADR, and MCF-7 cell lines 
were silenced for AHI-1 expression according to the 
manufacturer’s protocol. The gene-silencing efficiency 
of siRNA experiments was evaluated by WB analysis 
(Figure 4A). Afterwards, the IP of tumour cells silenced 
for AHI-1 was evaluated by the “transwell chamber in-
vasion assay”. The results of these experiments demon-
strated that the siRNA-mediated suppression of AHI-1 
mRNA significantly reduced the capability of migrating 
(Figure 4B) and invading (Figure 4C) of all tested cell 
lines. 
Migration and invasion processes of tumour cells in-
volve a protein complex scenario among which the sig-
nalling cascade of MAPKs. MAP kinases play an impor-
tant role in various physiological processes such as cell 
proliferation, differentiation, as well as cell invasion [1]. 
In addition, in our previous study it was demonstrated 
that the highest invasive potential was associated with 
the activation of several signalling proteins such as AKT, 
ERK, and FAK [24]. ERK is activated during invasion 
process by some growth factors and ECM components 
through signalling pathways involving Ras, Raf and 
MEK1/2. Once activated, ERK phosphorylates differ-
ent substrates including MLCK, calpain, paxillin and 
FAK (focal adhesion kinase) [26-28]. Activated ERK 
regulates membrane protrusions and focal adhesion 
turnover via phosphorylating MLCK and promotes fo-
cal adhesion disassembly via phosphorylating and acti-
vating calpain. Phosphorylation of FAK and paxillin by 
ERK may regulate focal adhesion dynamics, probably 
by influencing the paxillin-FAK interaction [29, 30]. 
FAK is involved in signal transduction from integrin-en-
riched focal adhesion sites that mediate cell interaction 
with the extracellular matrix [31, 32]. FAK-enhanced 
signals have been shown to mediate the survival of 
anchorage-dependent cells and are critical for efficient 
cell migration in response to growth factor receptor and 
integrin stimulation. Moreover FAK contributes to the 
secretion of matrix-metalloproteinases [31]. Akt pro-
motes cancer cell invasion via increased motility and 
metalloproteinase production [33]. In particular, it has 
been demonstrated that PI3K/Akt signaling contrib-
utes to translocation of MT1-MMP that can influence 
MMP-2 proteolytic activity and facilitate formation of 
invadopodia [32]. 
In order to investigate the possible role of Jbn in 
these pathways, we performed the analysis of the ac-
tivation of ERK, FAK, and Akt on the tested tumour 
cell lines, before and after AHI-1 silencing by RNA in-
terference experiments. The results obtained by west-
ern blotting experiments demonstrated that the sup-
pression of AHI-1 m-RNA reduced the expression of 
phosphorylated proteins in all tested cell lines with the 
exception of p-ERK in M14 ADR cells (Figure 5). Over-
expression of P-gp in tumour cells induces multidrug-
resistance and more aggressive phenotype [23, 34]. As 
we reported elsewhere [23], the M14 ADR cell lines 
overexpress the ATP-binding cassette (ABC) family 
member ABCB1 (P-glycoprotein, P-gp). In particular, 
our previous studies demonstrated that P-gp cooper-
ates with the adhesion molecule CD44 in the activation 
of ERK1/2 and p38 mitogen-activated protein kinase 
(MAPK) protein. Thus, the effect of AHI-1 m-RNA 
downregulation on ERK phosphorylation in M14 ADR 
cells was very likely counterbalanced by P-gp/CD44 
Figure 3
Scanning Electron Microscopy (SEM) observations of tumor 
cells invasion. (A, C, E, G) Upperside of porous membrane. (B, 
D, F, H) Lower side of porous membrane. (A, B) MDA-MB-231 
(C, D), LN229 (E, F), M14 ADR and (G, H) MCF-7 WT cells. An area 
of MatrigelTM degradation was seen around the invadopode of 
MDA-MB-231 (B) and LN229 (D) cells. The invadopode of M14 
ADR cells (F) was able to penetrates the extracellular matrix, 
apparently without degrading it, suggesting that an “amoe-
boid behaviour” was adopted. The MCF-7 WT cells scarcely in-
vaded the extracellular matrix (3 h).
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activation. Strikingly, a new AHI-1-BCR-ABL-JAK2 
interaction complex has been identified. This complex 
regulates transforming activities and drug resistance 
in CML stem/progenitor cells [20]. The WD40-repeat 
domain of AHI-1 interacts with BCR-ABL, whereas 
the N-terminal region interacts with JAK2 [20]. The 
ABL family of protein kinases links diverse extracellular 
stimuli to intracellular signalling pathways that control 
cell growth, survival, invasion, adhesion and migration 
[35-38]. Its role in solid tumors has not been compre-
hended until recently. However, the activation of ABL 
family proteins has been revealed in tumour cells de-
rived from breast, colon, lung and kidney carcinomas, 
as well as melanoma (reviewed in [39]). In particular, 
it has been demonstrated a key role of ABL signalling 
in the regulation of cell adhesion, motility, and invado-
podia through the modulation of the actin cytoskeleton 
[19, 40, 41] and the expression of several MMPs and 
other genes involved in epidermal growth factor recep-
tor (EGFR)-mediated invasion [42, 43]. It could be 
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Figure 4
(A) Densitometric analysis of Jbn expresssion after m-RNA AHI-1 silencing. (B, C) Effect of Jbn downregulation on (B) migration and 
(C) invasion potential of tumor cells. Experiments were performed in triplicate. SD are reported. (*) P-values lower than 0.05 were 
considered significant (siRNA jouberin vs siRNA CTR).
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speculated that the interaction of AHI-1/Jbn with BCR/
ABL/JAK2 complex lead to the activation of different 
pathways that via intermediate signalling proteins, such 
as AKT, ERK, and FAK upregulate cell proliferation, 
adhesion, migration and invasion.
CONCLUSIONS
In conclusion, our in vitro study for the first time dem-
onstrate the involvement of AHI-1 transcript Jbn in the 
migration and invasion of tumor cells of different his-
tological origin. In particular, the expression of Jbn is 
positively related to the IP of the tested tumor cells. 
In addition, it is more expressed in cells adopting an 
“individual/mesenchimal” behaviour. Noteworthy the 
AHI-1 m-RNA downregulation reduce the capability 
of migrating and invading the ECM in all tested cell 
lines. These results should candidate the product of the 
human AHI-1 gene Jbn as a new potential molecular 
target in anticancer therapy. Further studies are now 
in progress in order to analyse other signalling proteins 
involved downstream the AHI-1/ABL/JAK2.
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Western blot of p-FAK, p-AKT and p-ERK after m-RNA AHI-1 si-
lencing. Suppression of AHI-1 m-RNA reduced the expression 
of phosphorylated proteins in all tested cell lines with the ex-
ception of p-ERK expressed by M14 ADR cells. Changes in the 
levels of p-FAK, p-AKT and p-ERK after being normalized to the 
levels of a-tubulin are shown below each blot. Control samples 
are considered as the unit. The results shown are representa-
tive of three independent experiments.
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